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Figure 1. Pathophysiology of Allergic Rhinitis. Allergic rhinitis is an IgE
antibody-mediated hypersensitivity reaction typically occurring after exposure to a 
specific allergen. Allergen exposure triggers degranulation in mast cells, basophils 
and eosinophils. Degranulation results in the release of cytokines, histamines, and 
chemotactic factors. The release of these factors results in symptoms like 
rhinorrhea, nasal obstruction, nasal pruritus, and sneezing. The immune system has 
an intricate memory allowing a similar response to occur with subsequent exposure 
to identical or similar allergens.
Abstract
Introduction 
House-dust mite (HDM) induced allergic rhinitis (AR) is a chronic condition 
associated with rhinorrhea, nasal obstruction, nasal pruritus and sneezing. The current 
mainstay of treatment is intranasal corticosteroids, which have shown variable 
degrees of symptom control among patients. Immunotherapy works to increase 
peripheral immune tolerance by administration of the allergen itself. This study 
examined multiple randomized controlled trials to determine if sublingual 
immunotherapy (SLIT) is a viable treatment option for allergic rhinitis. 
• Allergic rhinitis affects approximately 10-30% of adults and 40% of children, 
with an estimated 60 million people suffering from the condition in the United 
States.
• The presence of allergic rhinitis significantly affects a person’s quality of life, 
contributing to issues like missed time at work or school, poor performance in 
daily activities, and lack of sleep. Total economic toll has been roughly $6 billion 
annually in the United States through direct and indirect costs of therapy and 
occupational burden.
• Not all patients experience equivalent resolutions of symptoms on intranasal 
corticosteroids and chronic use is required to achieve continued relief. 
• Immunotherapy not only has the potential to decrease acute symptoms of allergic 
rhinitis, but is also the only treatment with disease-modifying potential with long-
term use.
Figure 1. Pathophysiology of Allergic Rhinitis
Methods
Results
Study Statistical Power Adequate treatment timeline Blinding Intention-to-treat
Demoly et al 
(2016) A A A A
Guo et al 
(2017) I A A A
Nolte
(2016) A A A A
Okamoto 
(2018) A A A A
Okubo 







A = sample size > 400
M = sample size > 100
I = sample size <100
Timeline
A = well defined timeline (i.e. 
dosing up regulation, follow up 
and data collection outlined)
I = no defined timeline 
Blinding
A = double blind
M = single blind
I = no blinding 
Intention-to-treat
A = All patients enrolled in 
the study were included in 
the analysis
I = Not all patients enrolled 
in the study were included 
in the analysis









Demoly et al 
(2016) S S S S S
Guo et al 
(2017) N/A S S S S
Nolte
(2016) S S S S S
Okamoto 
(2018) N/A S NS N/A S
Okubo 




NS = not 
significant
N/A = not 
reported
TCRS = Total 
combined rhinitis 
score










S = ↓ in active 
groups compared 
to placebo 
NS = ↑ or no 









NS = ↑ or no 


















S = was 
determined safe
NS = was 
determined 
unsafe due to 
excessive 
toxicity
Table 1. Comparison of Results 








Demoly et al 
(2016)
Randomized, 
placebo-controlled 992 18-65 1 year 




Guo et al 
(2017) 
Randomized, 




placebo-controlled 1482 ≥ 12 1 year 
12 SQ or 
placebo





placebo-controlled 438 5-16 1 year 
300 IR or 
placebo





placebo-controlled 946 12-64 1 year 
10,000 JAU, 
20,000 JAU or 
placebo
TCRS, rhinitis 
symptoms, MS, QOL, 
symptom free days, 
symptom severe days 
KEY
SQ = Standardized quantity; JAU = Japanese Allergy Units;  TCRS = total combined rhinitis score; MS = medication score; QOL = quality of 
life; NSS = nasal symptom score; TNSS = total nasal symptom score, ACS = allergic conjunctivitis score; DSS = daily symptom score; DMS = 
daily medication score; AASS = average adjusted symptom score; RTSS = Rhinitis total symptom score; ARTSS; average rhinitis total symptom 
score; ARMS = average rescue medication score; individual symptom score
Table 2. Comparison of Study Designs 
The evidence compiled through five randomized controlled trials 
showed statistically significant symptom improvement in patients 
treated with SLIT in comparison to a placebo. Total combined rhinitis 
scores measured in three studies showed a reduction of greater than 15% 
in active groups. Total symptom scores showed a significant decrease in 
all studies analyzed. There were mixed significant and non-significant 
results in the measurement of medication scores after SLIT. Quality of 
life surveys showed improvement in active groups and the safety profile 





“Immunotherapy” AND “allergic rhinitis” AND 
“dust-mite” AND “sublingual”
• Published in the last 5 years (2015-2020)
• Human clinical trials 
• Published in peer reviewed journal  
• Systematic reviews or meta-analyses








Overall, the study designs were similar in that they all used randomized 
double-blind placebo-controlled trials, which contributed to the validity of the 
studies. However, variable dosing and outcome measurements make 
comparison difficult and reveal the need for standardization in this field. 
Extension of the one-year duration of intervention should be considered to 
determine the long-term effects of SLIT. 
Literature search was performed in April 2020
SLIT should be considered as an alternative or adjunct in the treatment of 
HDM-induced AR. SLIT has shown statistically significant symptomatic relief 
and a favorable safety profile. However, further research is required before 
SLIT can be recommended in place of the current standard of care. Cost-
benefit analysis and more long-term studies are necessary for better assessment 
of where SLIT belongs on the treatment continuum. 
